KPV (Lysine-Proline-Valine)

Comprehensive Research Analysis - Anti-Inflammatory Tripeptide for IBD, Wound Healing & Immune Modulation

Classification: Tripeptide, α-MSH Fragment, Anti-Inflammatory Agent, Immune Modulator Amino Acid Sequence: Lys-Pro-Val (K-P-V) Chemical Formula: C₁₇H₃₁N₅O₄ Molecular Weight: 369.46 Da (alt. 342.4 Da) FDA Status: NOT APPROVED - FDA Safety Concerns Noted WADA Status: No specific prohibition

1. Executive Summary

KPV is a tripeptide composed of lysine, proline, and valine, representing the C-terminal fragment of α-melanocyte stimulating hormone (α-MSH), an endogenously produced peptide hormone. KPV consists of three amino acids linked in linear sequence: L-lysine, L-proline, and L-valine, with molecular formula C₁₇H₃₁N₅O₄ and molecular weight of approximately 369.46 g/mol.

Unique Anti-Inflammatory Mechanism: Unlike its parent hormone α-MSH which binds melanocortin receptors, KPV does not bind melanocortin receptors. Instead, KPV enters the cell nucleus and inhibits inflammatory substances and molecules, working intracellularly to inhibit NF-κB and MAP kinase pathways, reducing pro-inflammatory cytokines (IL-1, IL-6).

Collagen Synthesis & Wound Healing: KPV enhances collagen production and cell migration, making it valuable in dermatology and regenerative medicine. The mechanism of wound healing involves inflammatory inhibition, angiogenesis, and collagen deposition.

Broad Clinical Potential: KPV shows promise for inflammatory bowel disease, skin conditions (psoriasis, eczema), and wound healing applications, targeting inflammation at cellular signaling level without broadly suppressing immunity.

Critical FDA Note: FDA has not identified any human exposure data on KPV and lacks important safety information, classifying it as a "potential significant safety risk" bulk drug substance.

Goal Relevance:

• Support for inflammatory bowel disease relief and management
• Enhancing wound healing and tissue repair after injuries or surgeries
• Reducing skin inflammation related to conditions like psoriasis and eczema
• Boosting immune response and reducing chronic inflammation
• Improving gut health and alleviating symptoms of digestive disorders like IBS

2. Chemical Structure & Composition

Molecular Weight: 369.46 Da (alternative source: 342.4 Da) Formula: C₁₇H₃₁N₅O₄ (alternative: C₁₆H₃₀N₄O₄)

Amino Acid Sequence (3 residues): K-P-V (Lys-Pro-Val)

• Position 1: L-Lysine (K)
• Position 2: L-Proline (P)
• Position 3: L-Valine (V)

Structural Characteristics

C-Terminal Fragment of α-MSH: KPV represents the last three amino acids from the C-terminus of α-melanocyte stimulating hormone.

Molecular Stability:

• Proline at position 2 provides significant protection against aminopeptidase activity (which degrades peptides from N-terminus)
• C-terminal valine is relatively resistant to carboxypeptidase degradation
• Half-life significantly longer than parent α-MSH peptide

Modified Analogs: Researchers have developed KPV analogs incorporating D-amino acids, lipophilic modifications, and chemical modifications to enhance resistance to proteolytic degradation, improve membrane permeability, and extend plasma half-life.

Size Advantage: Small tripeptide size enables rapid absorption and distribution, particularly via oral and topical routes.

3. Mechanism of Action

Unique Intracellular Anti-Inflammatory Mechanism

NO Melanocortin Receptor Binding: Critical distinction from parent α-MSH: KPV does NOT bind melanocortin receptors.

Intracellular Action:

1. Cellular Entry: KPV enters cells directly
2. Nuclear Translocation: Translocates to cell nucleus
3. Pathway Inhibition: Inhibits inflammatory signaling molecules

Molecular Pathway Inhibition:

• NF-κB pathway: Master regulator of inflammation
• MAP kinase pathway: Key signaling cascade for inflammatory response
• Result: Reduction in pro-inflammatory cytokines (IL-1, IL-6)

PepT1-Mediated Uptake

Peptide Transporter 1 (PepT1) Mechanism:

• PepT1 expressed in intestinal and immune cells
• hPepT1 has high affinity for KPV (Km ~160 μM)
• Among the lowest Kms reported for hPepT1
• Allows low doses to be efficiently targeted to intracellular compartment
• Enables oral bioavailability and direct access to epithelial/immune cells in gut

Clinical Significance: PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation, particularly relevant for inflammatory bowel disease treatment.

Collagen Synthesis & Wound Healing

Triple Mechanism for Tissue Repair:

1. Inflammatory Inhibition: Reduces pro-inflammatory cytokines
2. Angiogenesis: Promotes new blood vessel formation
3. Collagen Deposition: Stimulates collagen synthesis and fibroblast activity

Specific Wound Healing Actions:

• Enhances collagen production and cell migration
• Stimulates fibroblast activity
• Modulates collagen metabolism (reduces scar prominence)
• Promotes synthesis of collagen, speeding wound healing and maintaining tissue integrity

Immune Modulation Without Suppression

Critical Distinction: KPV modulates immunity without suppressing it, unlike corticosteroids or immunosuppressants. Does not suppress immune function, increase infection risk, or cause tissue thinning associated with long-term corticosteroid use.

Goal Archetype Integration

Primary Goal Alignment

When This Compound Makes Sense

Ideal Candidates:

• Inflammatory bowel disease (IBD) - ulcerative colitis, Crohn's disease
• Chronic gut inflammation, leaky gut syndrome, IBS with inflammatory component
• Autoimmune skin conditions - psoriasis, eczema, dermatitis
• Post-surgical or injury wound healing support
• Chronic low-grade inflammation with elevated CRP/ESR
• Seeking anti-inflammatory support without immunosuppression side effects
• Complementary therapy alongside conventional IBD treatments
• Older adults with age-related increased inflammation (inflammaging)

Clinical Scenarios:

• Patient intolerant to corticosteroids or seeking steroid-sparing approach
• Failed or partial response to conventional IBD therapies
• Chronic wound healing impairment
• Skin conditions resistant to topical treatments

When to Choose Something Else

4. Pharmacokinetics

Half-Life

Plasma Half-Life:

• 1-2 hours estimated
• Tissue concentrations may persist longer due to PepT1-mediated accumulation in target tissues

Anti-Inflammatory Duration: Anti-inflammatory effects can last 12-24 hours, longer than plasma half-life suggests.

Comparative Stability: KPV exhibits half-life significantly longer than parent α-MSH peptide, with measurable stability over several hours under physiological conditions.

Structural Protection:

• Proline at position 2 protects against aminopeptidase
• C-terminal valine resistant to carboxypeptidase

Bioavailability

Oral Bioavailability:

• Absorbed via intestinal PepT1 transporter
• Enables direct access to epithelial and immune cells in gut
• Peaks in plasma within 30-60 minutes (oral dosing)

Specific Bioavailability Data: While exact percentage values not published, KPV demonstrates therapeutic efficacy in preclinical models via oral administration, confirming functional oral bioavailability.

Route-Specific Absorption:

• Oral: PepT1-mediated intestinal uptake
• Topical: Transdermal iontophoretic delivery across microporated skin (research protocol)
• Injectable: Direct systemic distribution

Pharmacokinetic Challenges & Solutions

Delivery Challenges:

• Rapid loss of biological activity
• Short half-life
• Nonspecific distribution in vivo

Strategies Developed:

• Nanoparticle delivery systems (HA-functionalized nanoparticles for ulcerative colitis)
• Double-network hydrogels (KPV-binding hydrogel restores gut mucosal barrier)
• Structural modifications to extend half-life

5. Dosing Protocols

Clinical Trial Limitations

No Standard Treatment Protocol: No standard protocol established; not FDA-approved. Few to no human trials conducted; most studies on rodents.

Investigational Dosing Protocols

Topical Administration:

• Anecdotal Reports: 7.5mg twice daily
• Cream/Gel Formulations: 0.1-1% concentration
• Applications: Wounds, inflammatory skin conditions

Oral Administration:

• Anecdotal High Dose: 250mg twice daily
• Experimental Lower Dose: 10-20mg daily
• Research Protocol: 1-2 mg/kg daily in divided doses

Injectable Administration:

• Typical Range: 200-500 mcg once daily
• Approach: Gradual titration recommended
• Route: Subcutaneous injection

Preclinical Dosing (Animal Models)

IBD Studies: Oral administration of KPV reduces incidence of DSS- and TNBS-induced colitis, indicated by decreased pro-inflammatory cytokine expression.

Ulcerative Colitis Model: Orally targeted delivery via HA-functionalized nanoparticles efficiently alleviates ulcerative colitis.

Cycling & Duration

Recommendation: Long-term safety data lacking; use with clinical oversight and proper monitoring.

Age-Stratified Dosing

Important Note: No official age-specific dosing guidelines exist for KPV. The following represents extrapolated guidance based on general peptide pharmacology principles and known age-related physiological changes.

Age-Related Considerations:

• Elderly (65+): Older people tend to have more inflammatory molecules, possibly stemming from elevated levels of reactive oxygen species, which in turn can prolong wound-healing time. KPV may be particularly beneficial for age-related chronic inflammation (inflammaging), but start conservatively.
• Renal Function: Dose reduction warranted if eGFR <60 mL/min/1.73m^2
• Polypharmacy: Elderly patients on multiple medications require careful evaluation of potential interactions

Sex-Specific Considerations

Males:

• Standard dosing applies
• No known sex-specific pharmacokinetic differences
• Consider in conjunction with testosterone therapy if addressing chronic inflammation affecting hormonal health

Females:

• Standard dosing applies
• Pregnancy/Nursing: Not recommended for subjects who are nursing, may become pregnant, or are already pregnant
• Hormonal Cycle: No documented interactions, but some practitioners suggest avoiding during menstruation due to naturally elevated inflammatory state
• May be beneficial for inflammatory skin conditions that fluctuate with menstrual cycle

Marker-Based Dose Adjustment

Adjustment by Baseline Inflammatory Markers

Adjustment by Response Markers

6. Clinical Research & Evidence

Preclinical Inflammatory Bowel Disease Studies

PepT1-Mediated Mechanism:

• PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
• Effective in DSS-induced and TNBS-induced colitis models
• Reduced pro-inflammatory cytokine expression
• Preserved intestinal barrier function

Targeted Delivery Systems:

• Orally targeted delivery via hyaluronic acid-functionalized nanoparticles
• Efficiently alleviates ulcerative colitis in animal models
• KPV-loaded nanoparticles nontoxic and biocompatible with intestinal cells

Wound Healing & Dermatology Studies

Mechanism Validation: Wound healing mechanism associated with inflammatory inhibition, angiogenesis, and collagen deposition demonstrated in preclinical models.

Clinical Applications:

• Chronic wounds
• Scar reduction (modulates collagen metabolism)
• Inflammatory skin conditions (psoriasis, eczema)

Oxidative Stress & MAPK/NF-κB Studies

Fine Dust Protection: Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating MAPK/NF-κB pathway.

Transdermal Delivery Research

Iontophoretic Delivery: Transdermal iontophoretic delivery of KPV peptide across microporated human skin demonstrated feasibility of topical administration.

Safety & Toxicology

Biocompatibility: KPV-loaded nanoparticles nontoxic and biocompatible with intestinal cells.

Well-Tolerated in Animals: Generally well-tolerated based on various animal studies.

Human Trial Limitations

Critical Gap: Few to no human trials conducted; most KPV studies on rodents. Long-term human trials lacking.

7. Safety Profile

Overall Safety Assessment

Excellent Preclinical Safety:

• KPV considered extremely safe with minimal reported side effects
• Excellent safety profile with side effects rare and typically mild
• Long-term safety appears excellent with few side effects

Common Side Effects

Minimal Effects Reported:

• Temporary skin reactions with topical application (uncommon)
• Injection site reactions: redness, pain, swelling, bruising, itching

Safety Advantages

No Immune Suppression:

• Does NOT suppress immune function
• Does NOT increase infection risk
• Does NOT cause tissue thinning associated with long-term corticosteroid use
• Modulates immunity without suppressing it

Contraindications

Pregnancy & Nursing: Not recommended for subjects who are nursing, may become pregnant, or are already pregnant.

FDA Safety Concerns

CRITICAL: Lack of Human Safety Data: FDA has not identified any human exposure data on drug products containing KPV administered via any route. FDA lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans.

FDA Classification: FDA made statement in release about bulk drug substances considered to pose "potential significant safety risks". KPV's lack of safety studies is a red flag.

Professional Oversight Required

Medical Supervision: KPV peptide therapy generally considered safe when administered by qualified healthcare professional. May have potential side effects or interactions with other medications/supplements.

Drug Interactions - Comprehensive

Prescription Medications

Key Mechanistic Distinction

KPV vs. Immunosuppressants:

Unlike corticosteroids or systemic immunosuppressants, KPV offers targeted inflammation control - helping the body recover without compromising immune function. KPV modulates immunity without suppressing it.

This distinction means KPV may be safely combined with immunosuppressants under medical supervision, potentially allowing dose reduction of more toxic agents.

Other Compounds (Peptide Stacking)

Supplements

Foods/Timing

8. Administration & Practical Application

Routes: Oral, subcutaneous, topical Sites (SC): Abdomen, thigh (rotate sites) Reconstitution (SC): Bacteriostatic water for lyophilized powder

Oral Administration

Formulations:

• Capsules (high-dose: 250mg)
• Tablets (low-dose: 10-20mg)
• Oral spray (Integrative Peptides KPV Ultra Oral Spray)

Timing: May be taken with or without food (PepT1 transporter functional regardless)

Onset: Peaks in plasma within 30-60 minutes

Subcutaneous Injection

Protocol:

• Reconstitute lyophilized powder with bacteriostatic water
• Draw dose (200-500 mcg)
• Inject SC into abdomen or thigh
• Rotate injection sites
• Use insulin syringes

Frequency: Once daily

Titration: Start lower end of range and gradually increase based on response

Topical Application

Formulations:

• 0.1-1% cream or gel
• 7.5mg twice daily (anecdotal)

Applications:

• Wound healing
• Inflammatory skin conditions
• Scar reduction

Application Method:

• Clean area thoroughly
• Apply thin layer to affected area
• May cover with sterile dressing if appropriate

Storage & Handling

Lyophilized Powder:

• Store -20°C (freezer) long-term
• 2-8°C (refrigerator) short-term acceptable
• Protect from light and moisture

Reconstituted Solution:

• Refrigerate 2-8°C
• Use within 14-30 days
• Do NOT freeze
• Protect from light

9. Storage & Stability

Lyophilized Powder (Unreconstituted):

• Store at -20°C for long-term stability
• Can store 2-8°C short-term (weeks to months)
• Protect from light and moisture
• Stable for extended periods when properly stored

Reconstituted Solution:

• Refrigerate 2-8°C immediately after reconstitution
• Use within 14-30 days (varies by formulation)
• Do not freeze (destroys peptide structure)
• Protect from light (UV degradation)

Topical Formulations:

• Follow manufacturer storage guidelines
• Typically refrigerated storage
• Check expiration dates

Structural Stability: KPV exhibits measurable stability over several hours under physiological conditions, with proline and valine providing protection against proteolytic degradation.

FDA Classification: Classified as "potential significant safety risk" bulk drug substance.

Current Legal Status:

• Currently sold only as research chemical for laboratory use
• Multiple vendors state: Not medicines or drugs; not approved by FDA; not for human consumption
• Bodily introduction into humans or animals strictly forbidden by law
• For research use only

WADA Status: No specific prohibition on WADA Prohibited List (as of 2025)

Research Context: Despite regulatory status, significant preclinical and clinical research has highlighted considerable potential for managing inflammatory conditions, skin disorders, and microbial infections.

International Status: Similar regulatory status in most jurisdictions - available for research, not approved for therapeutic human use

11. Product Cross-Reference

Core Peptides Equivalent: Product page inaccessible during research; verify availability at https://www.corepeptides.com/product/kpv/

Typical Research Specifications:

• Form: Lyophilized powder
• Purity: >99% (HPLC)
• Common Sizes: 5mg, 10mg vials
• Storage: -20°C

Epiq Aminos: Product availability and pricing to be confirmed via https://orange-shrew-635172.hostingersite.com/

Alternative Suppliers:

• Peptide Sciences - KPV 5mg, 99% purity, USA-made
• Modern Aminos - KPV, 99% pure, US-made
• Integrative Peptides - KPV Ultra Oral Spray

Combination Products:

• BPC+KPV+PEA 500 (Healthgevity) - Triple peptide blend

Stacking Insights

• hat that means at a molecular level. So lysine positively charged amino acid that loves to interact with cell membranes.
• is the death spiral and it's screwing you up and you guys are running out.

12. References & Citations

1. Exploring Peptides - KPV
2. SteroidWiki - KPV (Lysine-Proline-Valine)
3. Robertson Wellness - KPV Miracle Peptide
4. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.
5. Yun J, et al. Orally targeted delivery of tripeptide KPV via HA-functionalized nanoparticles. Biomaterials. 2013.
6. Chandran AM, et al. Transdermal iontophoretic delivery of KPV peptide across microporated skin. J Pharm Sci. 2017.
7. Peptide Biologix - KPV Comprehensive Research Monograph
8. Peptides.org - KPV Dosage Calculator
9. Peptide Dosages - KPV Protocol
10. Regen Therapy - KPV Legal Status 2025
11. Innerbody - KPV Peptide Benefits & Safety 2025
12. Poterucha TJ, et al. Structural modification of tripeptide KPV by glycoalkylation. PLoS One. 2018.
13. Peptide Sciences - KPV 5mg Product
14. Modern Aminos - KPV For Sale

Document Version: 1.0 Last Updated: December 23, 2025 Development Status: Preclinical Research; Limited Human Data Regulatory Status: NOT FDA-Approved; "Potential Significant Safety Risk" - Research Chemical Only